哥伦比亚巴兰基亚某医疗中心接受类风湿性关节炎生物技术药物治疗的患者风险管理模型

Julia Aracelly Gonzalez Puertas, M. Duran, J. Durán, E. Manrique, B. Palácio, I. Pereira, E. Caballero, E Cabas
{"title":"哥伦比亚巴兰基亚某医疗中心接受类风湿性关节炎生物技术药物治疗的患者风险管理模型","authors":"Julia Aracelly Gonzalez Puertas, M. Duran, J. Durán, E. Manrique, B. Palácio, I. Pereira, E. Caballero, E Cabas","doi":"10.15406/PPIJ.2020.08.00274","DOIUrl":null,"url":null,"abstract":"Rheumatoid arthritis (RA) is a condition of multifactorial origin, characterized by inflammation and hyperplasia of the synovial membrane of the diarthrodial joints, predominantly of the hands and feet, in which there is production of autoantibodies, destruction of cartilage and subchondral bone, and it is usually accompanied by systemic manifestations such as nodules, cardiovascular disease and pulmonary involvement. Proper and early management improves the evolution and prognosis of the disease.1 The therapy comprises synthetic and biological disease modifying drugs which have serious side effects and, in the case of biological therapy, represents a potential risk of developing infectious diseases and other effects, associated with their mechanism of action.2 The main objective of this study is the identification of the drug-related problems (DRP) and classification of negative clinical outcome (NCO) according to their Necessity, Effectiveness and Safety of pharmacological therapy, through the implementation of a risk management program that prevents or minimizes these adverse health outcomes of patients with rheumatoid arthritis.","PeriodicalId":19839,"journal":{"name":"Pharmacy & Pharmacology International Journal","volume":"68 1","pages":"11-14"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk management model in patients receiving therapy with biotechnological medications for rheumatoid arthritis in a medical center in Barranquilla, Colombia\",\"authors\":\"Julia Aracelly Gonzalez Puertas, M. Duran, J. Durán, E. Manrique, B. Palácio, I. Pereira, E. Caballero, E Cabas\",\"doi\":\"10.15406/PPIJ.2020.08.00274\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rheumatoid arthritis (RA) is a condition of multifactorial origin, characterized by inflammation and hyperplasia of the synovial membrane of the diarthrodial joints, predominantly of the hands and feet, in which there is production of autoantibodies, destruction of cartilage and subchondral bone, and it is usually accompanied by systemic manifestations such as nodules, cardiovascular disease and pulmonary involvement. Proper and early management improves the evolution and prognosis of the disease.1 The therapy comprises synthetic and biological disease modifying drugs which have serious side effects and, in the case of biological therapy, represents a potential risk of developing infectious diseases and other effects, associated with their mechanism of action.2 The main objective of this study is the identification of the drug-related problems (DRP) and classification of negative clinical outcome (NCO) according to their Necessity, Effectiveness and Safety of pharmacological therapy, through the implementation of a risk management program that prevents or minimizes these adverse health outcomes of patients with rheumatoid arthritis.\",\"PeriodicalId\":19839,\"journal\":{\"name\":\"Pharmacy & Pharmacology International Journal\",\"volume\":\"68 1\",\"pages\":\"11-14\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacy & Pharmacology International Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/PPIJ.2020.08.00274\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy & Pharmacology International Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/PPIJ.2020.08.00274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

类风湿性关节炎(RA)是一种多因素起源的疾病,其特征是腹泻关节滑膜的炎症和增生,主要发生在手和脚,其中有自身抗体的产生,软骨和软骨下骨的破坏,通常伴有全身表现,如结节、心血管疾病和肺部受累。适当的早期治疗可改善疾病的发展和预后该疗法包括合成和生物疾病治疗药物,这些药物具有严重的副作用,并且在生物疗法的情况下,具有产生传染病和与其作用机制相关的其他影响的潜在风险本研究的主要目的是根据药物治疗的必要性、有效性和安全性来确定药物相关问题(DRP)和不良临床结果(NCO)的分类,通过实施风险管理计划来预防或最小化类风湿关节炎患者的这些不良健康结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Risk management model in patients receiving therapy with biotechnological medications for rheumatoid arthritis in a medical center in Barranquilla, Colombia
Rheumatoid arthritis (RA) is a condition of multifactorial origin, characterized by inflammation and hyperplasia of the synovial membrane of the diarthrodial joints, predominantly of the hands and feet, in which there is production of autoantibodies, destruction of cartilage and subchondral bone, and it is usually accompanied by systemic manifestations such as nodules, cardiovascular disease and pulmonary involvement. Proper and early management improves the evolution and prognosis of the disease.1 The therapy comprises synthetic and biological disease modifying drugs which have serious side effects and, in the case of biological therapy, represents a potential risk of developing infectious diseases and other effects, associated with their mechanism of action.2 The main objective of this study is the identification of the drug-related problems (DRP) and classification of negative clinical outcome (NCO) according to their Necessity, Effectiveness and Safety of pharmacological therapy, through the implementation of a risk management program that prevents or minimizes these adverse health outcomes of patients with rheumatoid arthritis.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Pilot study to compare the use of the national program drugs ALONE versus their combination with Artemisia Afra infusions for the treatment of pulmonary tuberculosis Gender differences in MS related pain, correlation with MRI lesion localization and burden of disease The efficacy and safety of silodosin-a review of literature Tribenoside–lidocaine combination in wound healing of hemorrhoids: a review of literature The effectively of favipiravir as antiviral therapy in the treatment of covid-19 in the several hospital in Blora, Indonesia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1